HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $10 to $12.
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $10 to $12.